Advertisement
ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,092,401, titled "Method and Apparatus for Producing Shock Waves for Medical Applications." The patent has a term extending to February 2027 and relates to a new method of producing shock waves utilizing a mechanically pressurized fluid.

In conventional methods to produce an acoustic shock wave, the acoustic wave is triggered by an electrical impulse. By contrast, the novel method presented in this patent is mechanical and comprises oscillating high pressure generated in the encapsulated fluid within the treatment applicator, which is used to produce focused acoustic shock waves. This innovation may create efficiencies in design, manufacture and usability of the Companys Pulsed Acoustic Cellular Expression (PACE®) technology and allows for unique device configurations and clinical applications that were not previously possible.

"We are pleased to be awarded this new patent as it has potential to be a significant asset in our product development efforts," stated Christopher M. Cashman, President and CEO of SANUWAVE. "This method of producing acoustic shock waves is different from the electrohydraulic method we use in our current products, and it could give rise to new clinical indications and alternative regulatory pathways for future product offerings."

About PACE

PACE, defined as Pulsed Acoustic Cellular Expression, delivers high-energy acoustic pressure waves in the shock wave spectrum to produce compressive and tensile stresses on cells and tissue structures which are designed to promote angiogenic and positive inflammatory responses, and quickly initiate the healing cascade. This is thought to result in microcirculatory improvement, including increased perfusion and blood vessel widening (arteriogenesis), the production of angiogenic growth factors, enhanced new blood vessel formation (angiogenesis) and the subsequent regeneration of tissue such as skin, musculoskeletal and vascular structures. PACE procedures trigger the initiation of an accelerated inflammatory response that speeds wounds into proliferation phases of healing and subsequently returns a chronic condition to an acute condition to help reinitiate the bodys own healing response.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (www.sanuwave.com) is an emerging regenerative medicine company focused on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVEs portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the bodys normal healing processes and regeneration. SANUWAVE intends to apply its PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE marked for treatment of the skin and subcutaneous soft tissue and recently completed its pivotal Phase III, Investigational Device Exemption (IDE) clinical trial in the U.S. for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved Ossatron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its Ossatron, Evotron™ and orthoPACE® devices in Europe.

Posted by Sean Fenske, Editor-in-Chief, MDT

Advertisement
Advertisement